Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Buyout In Amarin Corporation plc (ADR) (AMRN) Is Imminent!

Page 1 of 2

All throughout Wall Street we keep hearing about Amarin Corporation plc (ADR) (NASDAQ:AMRN) being bought out by some type of Big Pharma company in the future.  It’s all rumors circling around, but it’s one of the most talked about biotech topics on other popular stock trading websites. Amarin, though, in my opinion will be bought out eventually, because the market that the company targets is huge. That market is people that have high Triglycerides and need a pill to lower it, and the company has developed a drug named Vascepa that targets patients with high levels of Triglycerides.

Amarin Corporation plc (ADR) (NASDAQ:AMRN)Triglycerides profit in the making

There is big opportunity for the high Triglycerides market, as there are an estimated 70 million adults that have high levels of Triglycerides in the United States. So what does this mean for  patients that suffer with this ailment? Simply enough, the drug helps to lower high levels of Triglycerides, and most importantly the drug does this without raising bad cholesterol. With most Americans eating a lot of junk foods like fries, potato chips, and burgers, the number of potential patients will grow in the future, and the profits from Vascepa will increase over the years into the billions.

Big pharma scoping out Vascepa

So with Amarin targeting such a huge market with it’s drug Vascepa, a market that is expected to grow substantially, and patent cliffs for many big pharma companies looming in the coming years, I feel that Amarin is an obvious buyout target. Some of the companies that are probably looking at Amarin are GlaxoSmithKline plc (ADR) (NYSE:GSK) and Pfizer Inc. (NYSE:PFE). Both companies are seeing a lot of their patents expiring and need acquisitions to help bolster their portfolios to keep their revenue churning in. Glaxosmithkline has a few years until it gets desperate, but it needs to align itself with more drugs to stay on the top end of the spectrum. One of it’s drugs, “Avodart,” is used to treat an enlarged prostate gland in men, and it goes off patent in 2015. Glaxosmithkline reported sales in 2010 to be $937 million dollars, so Amarin’s Vascepa might be a nice fit to fill that void.

Pfizer has it’s share of upcoming patent expirations as well.  Pfizer’s “Celebrex” is used to treat osteoarthtritis, rheumatoid arthritis, and acute pain. It would make more sense for Pfizer to acquire Amarin because sales of “Celebrex” in 2011 were $2.5 billion and the patent on it expires in 2014. So Pfizer seems to be more in need as it would take a bigger loss with the patent expiration. That’s not to say that the other big pharma aren’t looking at Amarin as well, considering that Vascepa could bring in billions for any one of these companies–it’s a matter of what big pharma will win the race to taking Amarin over! Pfizer has $23 bilion in cash, while Glaxosmithkline has $24.3 billion cash on hand. So cash is not a problem for these big pharma companies, and I’m willing to bet that we will see some buyout offers for Amarin sooner rather than later.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!